The use of obesity medication increased significantly in Finland last year – many more Finns were treated for obesity compared to 2023. At the same time, opinions are divided on the effectiveness of the treatment.
A total of 75,000 Finns used medicines for weight loss or obesity treatment in 2024. This is an increase of 20% compared to 2023, according to the Social Insurance Institution of Finland (Kela). In five years, the number of users has increased more than elevenfold.
Semaglutide, sold under brands such as Ozempic and Wegovy, is the most popular. Originally designed as a drug for the treatment of type 2 diabetes, this type of medicine is not reimbursed if it is used for obesity alone. This means that Finns have to foot the bill themselves, which can be over €260 each month.
It is also unclear how effective this type of weight loss medication really is, but Pia Pajunen, an expert physician at Kela, says it is not a quick fix for losing weight.
– If you stop using the obesity medication, the weight often starts to increase again quickly. It’s important that both doctors and patients are aware that research shows these medications generally need to be used long-term, she says in a press release.